title: [Molecular genetic detection of minimal residual disease (MRD) in children with acute lymphoblastic leukemia].
abstract: The treatment of acute lymphoblastic leukemia (ALL) in childhood and adolescence achieves nowadays cure rates of more than 80%. The detection of minimal residual disease (MRD) via molecular genetic methods provides - in comparison with conventional clinical and biological parameters - much more sensitive approaches to monitor individual treatment response. Here we will discuss the molecular background and technical developments in the framework of the BFM-study group.
authors.affiliation: Institut für Humangenetik, Universität Heidelberg, Heidelberg, Germany.
authors.forename: R
authors.initials: R
authors.lastname: Koehler
authors.forename: C R
authors.initials: CR
authors.lastname: Bartram
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001215:Asparaginase / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D003561:Cytarabine / Q000009:adverse effects / Q000627:therapeutic use; D003630:Daunorubicin / Q000009:adverse effects / Q000627:therapeutic use; D005819:Genetic Markers / Q000235:genetics; D006801:Humans; D015122:Mercaptopurine / Q000009:adverse effects / Q000627:therapeutic use; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D018365:Neoplasm, Residual / Q000145:classification / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics*; D016133:Polymerase Chain Reaction; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000145:classification / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics*; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D011379:Prognosis; D011446:Prospective Studies; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D005819:Genetic Markers; D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D015122:Mercaptopurine; D001215:Asparaginase; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin